Literature DB >> 20046814

Bronchiectasis, part 2: Management.

Meeta Prasad1, Gregory Tino.   

Abstract

Systemic antibiotics are the mainstay of the management of acute exacerbations of bronchiectasis. Antibiotic selection should include coverage for Streptococcus pneumoniae and Haemophilus influenzae; particular attention also should be paid to the presence of Staphylococcus aureus and Pseudomonas species. The duration of antibiotic therapy is not well-established, but most clinicians recommend a prolonged course, often longer than 3 weeks. There is some evidence that long-term low-dose macrolide therapy can reduce the incidence of acute exacerbations and decrease sputum production. There also may be a role for the use of inhaled antibiotics. Airway clearance strategies, such as chest percussion and postural drainage, are clearly useful in patients with cystic fibrosis and may be useful in other patients with bronchiectasis. Surgical resection can be considered if a patient has localized disease that is refractory to medical management or if he/she is unwilling to undergo long-term medical therapy.

Entities:  

Year:  2008        PMID: 20046814      PMCID: PMC2799935     

Source DB:  PubMed          Journal:  J Respir Dis        ISSN: 0194-259X


  30 in total

1.  A comparative study on the efficacy of levofloxacin and ceftazidime in acute exacerbation of bronchiectasis.

Authors:  K W Tsang; W M Chan; P L Ho; K Chan; W K Lam; M S Ip
Journal:  Eur Respir J       Date:  1999-11       Impact factor: 16.671

2.  Inhaled fluticasone in bronchiectasis: a 12 month study.

Authors:  K W Tsang; K C Tan; P L Ho; G C Ooi; J C Ho; J Mak; G L Tipoe; C Ko; C Yan; W K Lam; M Chan-Yeung
Journal:  Thorax       Date:  2005-03       Impact factor: 9.139

3.  Inhaled steroids improve quality of life in patients with steady-state bronchiectasis.

Authors:  Miguel A Martínez-García; Miguel Perpiñá-Tordera; Pilar Román-Sánchez; Juan Jose Soler-Cataluña
Journal:  Respir Med       Date:  2006-01-24       Impact factor: 3.415

4.  Surgical management of bronchiectasis.

Authors:  T Agasthian; C Deschamps; V F Trastek; M S Allen; P C Pairolero
Journal:  Ann Thorac Surg       Date:  1996-10       Impact factor: 4.330

5.  Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group.

Authors:  A E O'Donnell; A F Barker; J S Ilowite; R B Fick
Journal:  Chest       Date:  1998-05       Impact factor: 9.410

6.  A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis.

Authors:  Paul Scheinberg; Eric Shore
Journal:  Chest       Date:  2005-04       Impact factor: 9.410

7.  Mucus clearance and lung function in cystic fibrosis with hypertonic saline.

Authors:  Scott H Donaldson; William D Bennett; Kirby L Zeman; Michael R Knowles; Robert Tarran; Richard C Boucher
Journal:  N Engl J Med       Date:  2006-01-19       Impact factor: 91.245

8.  Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum.

Authors:  Evangelia Daviskas; Sandra D Anderson; Kerry Gomes; Peter Briffa; Belinda Cochrane; H-Kim Chan; Iven H Young; Bruce K Rubin
Journal:  Respirology       Date:  2005-01       Impact factor: 6.424

9.  Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

Authors:  B W Ramsey; H L Dorkin; J D Eisenberg; R L Gibson; I R Harwood; R M Kravitz; D V Schidlow; R W Wilmott; S J Astley; M A McBurnie
Journal:  N Engl J Med       Date:  1993-06-17       Impact factor: 91.245

10.  Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis.

Authors:  E Yalçin; N Kiper; U Ozçelik; D Doğru; P Firat; A Sahin; M Ariyürek; G Mocan; N Gürcan; A Göçmen
Journal:  J Clin Pharm Ther       Date:  2006-02       Impact factor: 2.512

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.